EMA approves Biocon Biologics' monoclonal antibodies facility in Bengaluru, India, for biosimilar Bevacizumab production.
European Medicines Agency (EMA) approves Biocon Biologics' new monoclonal antibodies facility in Bengaluru, India, to produce biosimilar Bevacizumab, a cancer treatment drug. The approval enhances the company's capacity to address patient needs across European markets and renews Good Manufacturing Practice (GMP) certificates for the Bengaluru and Malaysia facilities.
June 24, 2024
7 Articles